Daily Snapshot

Daily Snapshot – 28 September 2022

In a world of bad news, and I’m not trying to hide the fact there is a lot, how great is it to see the news of Biogen and Eisai’s clinical trial which showed their Alzheimer’s drug slowed the rate at which the disease progresses. Over the past 25 years around 99% of Alzheimer's studies have failed. Simon Baker our resident healthcare expert found 16 amyloid antibodies that have failed before this one and found 342 Alzheimer's drug whose development has been suspended so this is really quite rare and something to cheer about.

The content on this site is available to all Redburn clients as part of Redburn Execution’s standard service. It is not considered substantive research and there are no commercial implications to viewing these pages.

Please enter your email address below to view this page. If you are still unable to access the page, please speak to your account manager.